← back to search

Maurizio Facheris

AbbVie (United States) · US
Area of research
Neurology · Epidemiology
Research interest
Research interests include Medicine, Parkinson's disease, Carbidopa, Levodopa, Genetics, and Biology.
h-index
citations
719
works
8
NIH funding
primary concept
email

Recent publications

Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance
Clinical Parkinsonism & Related Disorders 2024cited by 32position: middledoi
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Neurology and Therapy 2023cited by 104position: middledoi
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial
The Lancet Neurology 2022cited by 190position: middledoi
Efficacy and safety of foslevodopa/foscarbidopa versus oral carbidopa/levodopa in advanced Parkinson's disease patients: Design of a phase 3, randomized, double-blind, double-dummy, active controlled 12-week trial
Journal of the Neurological Sciences 2021cited by 2position: firstdoi
Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease
Movement Disorders 2018cited by 93position: middledoi
Effect of Levodopa‐carbidopa Intestinal Gel on Non‐motor Symptoms in Patients with Advanced Parkinson's Disease
Movement Disorders Clinical Practice 2017cited by 61position: middledoi
Large-scale replication and heterogeneity in Parkinson disease genetic loci
Neurology 2012cited by 130position: middledoi
A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants
Journal of Medical Genetics 2012cited by 107position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David G. Standaert · University of Alabama at Birmingham5 papers (2017–2023)Victor S.C. Fung · The University of Sydney4 papers (2018–2024)Weining Robieson · AbbVie (United States)4 papers (2018–2023)Nahome Fisseha · Virginia Commonwealth University3 papers (2021–2024) · 3 papers (2022–2024)Saritha Talapala · AbbVie (United States)3 papers (2022–2024) · 2 papers (2023–2024) · 2 papers (2022–2023)Robert A. Hauser · University of South Florida2 papers (2022–2024)Jia Jia · The First Affiliated Hospital, Sun Yat-sen University2 papers (2023–2024)John T. Slevin · University of Kentucky2 papers (2017–2018)Susan Eaton · Case Western Reserve University2 papers (2017–2018)Anna Jeong · AbbVie (United States)2 papers (2022–2024) · 2 papers (2022–2024)Manon Bouchard · Université Laval2 papers (2023–2024)Amy M. Spiegel · AbbVie (United States)2 papers (2023–2024)Krai Chatamra · AbbVie (United States)2 papers (2017–2018)Ramon L. Rodriguez · University of Central Florida2 papers (2017–2018)Filip Bergquist · Lund University2 papers (2023–2024)Coleen Hall · AbbVie (United States)2 papers (2017–2018)